MedTrace Logo

Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World

NCT05381753 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2026-02-11

No results posted yet for this study

Summary

This study is an observational, multicenter, Real-word study to evaluate the safety and clinical efficacy of avapritinib in Chinese subjects with GIST.

Conditions

Interventions

DRUG

Avapritinib

Avapritinib will be administered orally at the starting of 300 mg once daily as the label recommended. Investigators can adjust the dosage, frequency, and duration as needed.

DRUG

Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al )

Investigators will decide which TKI to use as well as the dosage, frequency, and duration.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-29
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05381753 on ClinicalTrials.gov